by qfrsolutions | Aug 1, 2016 | News
Source: Real Money Valeant Pharmaceuticals’ (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels — especially as the drugmaker’s roughly $31 billion debt package did...
by qfrsolutions | Jul 25, 2016 | News
Source: CNBC Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (FBIO), launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased...
by qfrsolutions | Jul 13, 2016 | News
Source: The Wall Street Journal Michael Pearson has sold nearly $100 million of his stock in Valeant Pharmaceuticals International Inc. in the past two weeks, according to securities filings, following his firing as the troubled drugmaker’s chief executive in...
by qfrsolutions | Jul 8, 2016 | News
Source: Galderma, a global leader focused on medical solutions in skin health, today announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration (FDA) for Differin® Gel (adapalene gel 0.1%) as an...
by qfrsolutions | Jul 5, 2016 | News
Source: LEO Pharma has entered a strategic partnership with AstraZeneca for new medicines for atopic dermatitis and psoriasis, major skin diseases with a significant unmet medical need. Under the move, LEO gains a the global licence to AZ’ tralokinumab in skin...
by qfrsolutions | Jun 28, 2016 | News
Source: Teva’s massive agreement to buy Allergan’s generics business continues to ripple its way through the industry. Australia’s Mayne Pharma has scooped up 42 products from the two companies, which are intent on winning antitrust clearance for...
